We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for Teladoc in 2019, After a Strong 2018?
Read MoreHide Full Article
Telehealth leader, Teladoc Health, Inc. (TDOC - Free Report) is poised for good growth in 2019 after making a strong finish to the year 2018.
The company by virtue of its expansive virtual care delivery solution is poised to grow in the rapidly growing telehealth industry.
Teladoc is fast gaining ground in the rapidly growing telehealth services industry in the United States with ample scope for flourish owing to concerning health care cost following inefficient care, duplication of services, significant waste and extreme variation in access, cost and quality of care.
Teladoc has the capability to address this inefficiency by providing superior quality of care through platform that caters to consumer demand and physician availability in real-time and in various modalities such as video, web, mobile and telephone. Moreover, the emergence of technology via big data and analytics, cloud-based solutions, online video and mobile applications offers the company with huge opportunity for growth.
Teladoc’s strategy to complement its organic growth with inorganic means is commendable. The acquisitions of HealthiestYou, Best Doctors, Advance Medical have increased the breadth of its business. The latest acquisition of Advance Medical has given it a global exposure, which should enable it to harness the international markets.
A report by Medgadget says that Global Telehealth Market is expected to witness a healthy CAGR of 29.8% by 2023. Teladoc is one of the few companies that should gain from the global demand for telehealth given its acquisition of Advance Medical which has expanded the company’s business in Latin America and Asia. Advance Medical allows Teladoc to deliver care in 125 countries in more than 120 languages.
The Infrastructural support from the recent acquisitions of Advance Medical and Best Doctors enabled the company to form a virtual care service called Teladoc Global Care, which will be effective beginning 2019. This new platform should expand the company’s business, which was until now restricted within the United States.
We expect a huge the company’s Global Care platform to attract huge traction as employers and insurers demand international services for telehealth, due to the growing number of expatriates.
We thus expect the company’s revenues, (which witnessed a CAGR of 82% from 2013-2017 and further growth by 89% in the first nine months of 2018) to be aided by increased business from international operations, while its U.S. business is already doing well.
Teladoc, carrying a Zacks Rank #3 (Hold), has gained 39% year to date, compared with the industry’s growth of 9%. The company’s strong growth should keep the rally in the shares alive going forward.
BioTelemetry, beat estimates in each of the four quarters with an average positive surprise of 55.6%. Medpace and AMN Healthcare beat estimates in three of the last four reported quarters with an average positive surprise of 22.8%, 23.97% and 4.17%, respectively.
Will You Make a Fortune on the Shift to Electric Cars? Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
What's in Store for Teladoc in 2019, After a Strong 2018?
Telehealth leader, Teladoc Health, Inc. (TDOC - Free Report) is poised for good growth in 2019 after making a strong finish to the year 2018.
The company by virtue of its expansive virtual care delivery solution is poised to grow in the rapidly growing telehealth industry.
Teladoc is fast gaining ground in the rapidly growing telehealth services industry in the United States with ample scope for flourish owing to concerning health care cost following inefficient care, duplication of services, significant waste and extreme variation in access, cost and quality of care.
Teladoc has the capability to address this inefficiency by providing superior quality of care through platform that caters to consumer demand and physician availability in real-time and in various modalities such as video, web, mobile and telephone. Moreover, the emergence of technology via big data and analytics, cloud-based solutions, online video and mobile applications offers the company with huge opportunity for growth.
Teladoc’s strategy to complement its organic growth with inorganic means is commendable. The acquisitions of HealthiestYou, Best Doctors, Advance Medical have increased the breadth of its business. The latest acquisition of Advance Medical has given it a global exposure, which should enable it to harness the international markets.
A report by Medgadget says that Global Telehealth Market is expected to witness a healthy CAGR of 29.8% by 2023. Teladoc is one of the few companies that should gain from the global demand for telehealth given its acquisition of Advance Medical which has expanded the company’s business in Latin America and Asia. Advance Medical allows Teladoc to deliver care in 125 countries in more than 120 languages.
The Infrastructural support from the recent acquisitions of Advance Medical and Best Doctors enabled the company to form a virtual care service called Teladoc Global Care, which will be effective beginning 2019. This new platform should expand the company’s business, which was until now restricted within the United States.
We expect a huge the company’s Global Care platform to attract huge traction as employers and insurers demand international services for telehealth, due to the growing number of expatriates.
We thus expect the company’s revenues, (which witnessed a CAGR of 82% from 2013-2017 and further growth by 89% in the first nine months of 2018) to be aided by increased business from international operations, while its U.S. business is already doing well.
Teladoc, carrying a Zacks Rank #3 (Hold), has gained 39% year to date, compared with the industry’s growth of 9%. The company’s strong growth should keep the rally in the shares alive going forward.
Some better-ranked stocks in the same space are BioTelemetry, Inc. (BEAT - Free Report) , Medpace Holdings, Inc. (MEDP - Free Report) and AMN Healthcare Servcies Inc. (AMN - Free Report) . While BioTelemetry carries a Zacks Rank #1 (Strong Buy), the other two carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
BioTelemetry, beat estimates in each of the four quarters with an average positive surprise of 55.6%. Medpace and AMN Healthcare beat estimates in three of the last four reported quarters with an average positive surprise of 22.8%, 23.97% and 4.17%, respectively.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>